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Abstract 
 
BAFF deficiency in mice impairs B cell development beyond transitional stage 
1 in the spleen and thus severely reduces the size of follicular and marginal 
zone B cell compartments. Moreover, humoral immune responses in these 
mice are dramatically impaired. We now addressed the question whether the 
decrease in mature B cell numbers and the reduced humoral immune 
responses in BAFF-deficient mice could be overcome by the injection of 
recombinant BAFF. We therefore engineered a recombinant protein 
containing the human IgG1 Fc moiety fused to receptor binding domain of 
human BAFF (Fc-BAFF). At one week after the second injection of this fusion 
protein a complete rescue of the marginal zone B cell compartment and a 
50% rescue of the follicular B cell compartment was observed. Moreover 
these mice mounted a T cell-dependent humoral immune response 
indistinguishable from wild type mice. By day 14 upon arrest of Fc-BAFF 
treatment mature B cell numbers in the blood dropped by 50%, indicating that 
the life span of mature B cells in the absence of BAFF is 14 days or less.  
Collectively these findings demonstrate that injection of Fc-BAFF in BAFF-
deficient mice results in a temporary rescue of a functional mature B cell 
compartment.  
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Introduction 
 
The first steps of B cell development take place in the bone marrow, where 
cells are selected for productive rearrangement of the immunoglobulin heavy 
and light chain genes and subsequently for the surface expression of a proper 
non-autoreactive B cell receptor (BCR) [1-4]. These immature B cells then 
leave the bone marrow and differentiate further in the spleen through 
transitional phases 1, 2 and 3 (T1, T2 and T3). These stages can be 
distinguished by the expression of CD21, CD23, IgM and IgD, T1 being 
defined as CD21-CD23-IgMhighIgDlow, T2 CD21+CD23+IgMhighIgDhigh and T3 
CD21+CD23+IgMlowIgDhigh [5-9]. Transitional B cells then differentiate into 
follicular or marginal zone mature B cells (FO B and MZB). The hallmark of 
the transition from immature to mature B cells is the loss of CD93 cell surface 
marker [6].  
B cell activator factor of the TNF family (BAFF) [10], a member of the Tumor 
Necrosis Factor (TNF) family, has been identified as the key factor in the 
survival of immature B cells as they differentiate to mature B cells. BAFF-
deficient mice were initially described as having a major block at the T1 stage 
of B cell differentiation and very low numbers of mature B cells [11]. It was 
shown later that B cells beyond the T1 stage do exist in BAFF-deficient mice, 
but that they are present in reduced number and fail to express CD21 and 
CD23 [Gorelik 2004, JI 172:762]. BAFF binds to three different receptors, 
BAFF-R, TACI and BCMA [12-14]. Among these receptors, only BAFF-R 
deficiency recapitulates the B cell lymphopenia observed in BAFF-deficient 
mice, demonstrating that BAFF binding to BAFF-R is the critical event in 
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mature B cell differentiation [15-18]. Upon binding, BAFF-R induces the 
activation of the NF-κB pathway, which then induces the expression of anti-
apoptotic members of the Bcl-2 family [19, 20]. Transgenic expression of Bcl-
2 in B cells of BAFF-deficient mice rescue mature FO B cells development but 
not MZB [21]. This suggests that at transitional stage survival signals are 
necessary and sufficient to allow differentiation into the FO B cell lineage, 
whereas it is not sufficient to induce MZB differentiation. 
BAFF-mediated survival signals are not only required during the transition 
from immature to mature B cells but also during the entire life of naïve B cells. 
Inhibition of BAFF-R signalling by injection of TACI-Ig, BAFF-R-Ig or BAFF-R-
specific antagonist antibodies in wild type mice results in the rapid loss of 
mature B cells [22-25].  
We demonstrate here that injection of BAFF-deficient mice with a recombinant 
Fc-BAFF protein can rescue mature B cell development and leads to the 
formation of a normal splenic B cell zone architecture. Moreover, treatment 
completely restored the ability of BAFF-deficient mice to mount an antibody 
response against T-dependent antigen.  When Fc-BAFF treatment was 
interrupted, mature B cell population decreased with an estimated half-life 
time of ≤ 14 days.   
 Altogether, these findings demonstrate that BAFF-deficiency can be almost 
completely corrected by exogenous administration of recombinant Fc-BAFF. 
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Results 
 
Fc-BAFF recombinant protein forms oligomeric complexes, binds to 
mouse BAFF receptors and induces survival of sorted mouse mature B 
cells. 
 
We generated a recombinant fusion protein consisting of the TNF homology 
domain of the human BAFF and the Fc part of human IgG1 (Fc-BAFF) (fig. 
1a). This protein was produced in Chinese hamster ovary cells and purified 
from supernatants by affinity chromatography on Protein A. Fc-BAFF had 
apparent molecular weights of 50 kDa and 100 kDa by SDS-PAGE under 
reducing and non-reducing conditions, indicating that a disulfide bond 
between two Fc moieties led to the formation of dimers (fig. 1b). 
Crystallographic studies demonstrated that the soluble form of hBAFF forms 
trimers [26]. We therefore expected Fc-BAFF protein to multimerize under 
native conditions. Indeed, when analyzed on a Superdex-200 gel filtration 
column, Fc-BAFF eluted inbetween the 440 and 232 kDa markers, in 
agreement with the predicted size of ~300 kDa for hexameric Fc-BAFF (fig. 
1c). These data strongly suggest that Fc-BAFF indeed contains 2 trimeric 
hBAFF portions and 3 dimeric Fc parts assembled in a hexamer (fig. 1d). 
Previously it was shown that FasL-Fc forms a similar type of complex [27]. 
We next addressed the binding properties of Fc-BAFF to mouse BAFF 
receptors, BAFF-R, TACI and BCMA. Fc-BAFF binding could be detected on 
transfectants expressing BAFF-R and TACI but could not be observed on 
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cells expressing BCMA (fig. 1e) reflecting the different affinity of BAFF for its 
receptors.  
We then tested Fc-BAFF biological activity in vitro. For this purpose, we 
addressed the ability of Fc-BAFF to induce survival of mature splenic B cells. 
As shown in figure 2, the vast majority of CD19+ B cells kept for 5 days in 
culture in the absence of survival signals were propidium iodide positive, but 
the addition of 1 to 100 ng/ml of Fc-BAFF induced B cell survival in a dose-
dependent manner. Altogether, these data show that recombinant Fc-BAFF 
has similar receptor-binding properties and in vitro biological activity as BAFF. 
 
Fc-BAFF treatment rescues B cell development in BAFF-deficient mice.  
 
In BAFF deficient mice, B cells development beyond the transitional 1 stage is 
impaired due to lack of BAFF-mediated survival/differentiation signals (fig.3A 
and [11]). Having demonstrated Fc-BAFF biological activity on mouse mature 
B cells in vitro, we wondered whether the mature B cell pool could be rescued 
in BAFF-deficient mice by exogenous administration of the recombinant 
cytokine. As shown in figure 3, Fc-BAFF treatment rescued mature B cell 
development to a very large extent. Control BAFF-deficient mice had very low 
percentages of CD19+CD93- mature B cells and among them very few 
expressed CD21 and/or CD23 (fig 3a and b, middle panels). In contrast, Fc-
BAFF-treated mice had a mature B cell compartment (CD19+CD93-), which 
was about 70% of that found in wild type controls (fig.3a and c). Moreover 
CD21 and CD23 expression on rescued mature B cells revealed that 
treatment resulted in the formation of a MZB compartment whose size was 
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indistinguishable from WT mice whereas the number of follicular B cells that 
could be rescued was about half that found in WT mice (fig. 3b and c).     
Spleen sections from WT, BAFF-deficient control and BAFF-deficient mice 
treated with Fc-BAFF stained for IgM and CD90 (Thy1) revealed that Fc-
BAFF treatment led to a complete normalization of B and T cell architecture 
(fig. 4a). Moreover, staining with anti-IgM and the anti-metalophilic 
macrophage-specific antibody Moma revealed that Fc-BAFF treatment also 
resulted in the formation of a correctly localized MZB cell compartment 
(fig.4b).  
 
 Fc-BAFF treatment rescues mature B cell function 
 
Given the ability of Fc-BAFF injections to rescue B cell development, we 
wondered whether treatment of BAFF-deficient animals would improve their 
ability to mount an antibody response upon immunization with a T-dependent 
antigen. As shown in figure 5, humoral immune response in BAFF-deficient 
mice was significantly lower than in WT mice. In marked contrast, Fc-BAFF 
treatment significantly improved immune response in BAFF-deficient mice that 
became as efficient as in WT mice. 
In conclusion, Fc-BAFF treatment not only rescues B cell development in 
BAFF-deficient mice but also entirely rescues an immune response measured 
by antibody production toward a T-dependent antigen.    
 
Decrease of mature B cells upon Fc-BAFF withdrawal. 
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In order to investigate the fate of the mature B cells rescued by Fc-BAFF upon 
treatment arrest, we injected a cohort of BAFF-deficient mice at day 0 and 14 
with recombinant Fc-BAFF and monitored the percentage of mature B cells in 
peripheral blood over time. As shown in figure 6a, one week after the last 
injection of Fc-BAFF about 20% CD19+CD93- mature B cells could be 
detected in the blood, which is about half that found in the blood of wild type 
mice (data not shown). Two weeks later, this percentage had dropped to 
around 10%, and yet another two weeks later, percentages of mature B cells 
were identical to those found in untreated BAFF-deficient mice (fig 6a). These 
findings indicate that the half-life of mature B cells in the absence of BAFF is 
maximally 2 weeks. However, this is probably an overestimation since the 
half-life of the Fc-BAFF also has to be taken into account. In order to 
determine the half-life of Fc-BAFF in the serum we injected wild type mice 
with 50 µg of recombinant protein and measured its decay over time. As 
shown in figure 6b Fc-BAFF levels dropped rather quickly and became at the 
border of detection 96 hrs after injection. Based on these results, the half-life 
of Fc-BAFF in the serum was around 13 hrs. However, the half-life of Fc-
BAFF biological activity might well be longer, as B cells from BAFF-deficient 
taken 96 hrs after Fc-BAFF administration still had very significant amounts of 
Fc-BAFF bound on their cell surface (fig. 6c).    
Overall, data presented here demonstrate that the half-life of mature B cells in 
the absence of BAFF is maximally 14 days. 
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Discussion 
BAFF and BAFF-R deficiency in mice results in impaired B cell development 
beyond the T1 B cell stage [11]. Therefore these mice have reduced number 
of mature B cells and their capacity to mount a humoral immune response is 
impaired [18] (Schiemann, 2001). Here we demonstrate that the BAFF 
deficiency can be almost completely corrected by administration of 
recombinant Fc-BAFF protein. Fc-BAFF treatment rescued the production of 
both mature follicular and marginal zone B cells and resulted in a completely 
normal splenic T and B cell zone architecture. Moreover, injected BAFF-
deficient mice demonstrated an ability to mount a T-dependent immune 
response that was comparable to WT mice. The survival of mature B cells in 
these mice was strictly dependent on the constant injection of Fc-BAFF, 
because CD19+CD93- peripheral blood B cells dropped upon treatment 
interruption. The findings reported here indicate that the half-life time of 
mature B cells in the absence of BAFF is maximally 14 days. However, an 
accurate determination of the half-life of mature B cells in absence of BAFF-
mediated signals would require more careful monitoring of the rate by which 
Fc-BAFF bioavailability decreases. By ELISA, we showed that the half-life of 
Fc-BAFF in the serum is about 13 hrs. However, these findings do not 
exclude that Fc-BAFF could still deliver survival signals even when 
undetectable in serum. Recently we showed that the half-life time of mature B 
cells in mice injected with an antagonistic anti-BAFF-R mAb is about 7 days 
(22). Furthermore it has been demonstrated that injection of TACI-Fc or 
BAFFR-Fc fusion proteins lead to the disappearance of mature B cells with 
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very similar kinetics [23, 24]. Therefore, the 14 days half-life measured here is 
most likely and overestimation.  
Survival of mature B cells is also dependent on the expression of the BCR 
[28, 29]. Conditional ablation of BCR expression by mature B cells shortens 
their life span from 100 to 3 to 6 days [28, 29].  
Recently it has been demonstrated that BCR signalling induces the 
expression of the non-canonical NF-κB factor p100, which is required for 
BAFF-R mediated survival signals [30]. Moreover it has been shown that BCR 
cross-linking on mature B cells results in the up regulation of BAFF-R 
expression [31]. Taken together these findings suggest a strong connection 
between BCR and BAFF-R signalling in mature B cell survival. This provides 
an explanation why BCR-less and BAFF-less mature B cells display similar 
half-lives.  
 Treatment of BAFF-deficient mice with Fc-BAFF induced a significant and 
reproducible bias toward marginal zone B cells generation. Previously, a 
similar bias was observed in B lymphopenic rodents [32-34]. Therefore, the 
more efficient generation of MZB cells over follicular B cells in BAFF-deficient 
mice upon Fc-BAFF treatment might just reflect the B lymphopenic situation.  
However, the fact that BAFF-transgenic [35-37] mice and mice treated with 
Fc-BAFF display similarly increased MZB to follicular B cell ratio offer other 
mutually not exclusive explanations for the MZB bias observed upon Fc-BAFF 
administration, arguing against the only effect of B cell lymphopenia [35, 36]. 
First, BAFF might be a growth factor for MZB and increased BAFF availability 
may enlarge this B cell compartment. Second, follicular B cells may 
differentiate into MZB under the influence of high BAFF concentrations. And, 
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third, the number of immature B cells that differentiate into the MZB 
compartment may be determined by the amount of BAFF available. Recently 
it was shown that ectopic expression of the anti-apoptotic Bcl-2 gene in B 
cells can rescue follicular B but not MZB cell development in BAFF-deficient 
mice [21]. Based on these findings it was argued that BAFF plays an 
instructive role in the generation of MZB cells. If true, the amount of available 
BAFF might indeed determine the size of the MZB compartment.    
Recently it was shown that T and B cell deficiencies in mice lacking IL-7 could 
be overcome by the injection of IL-7 or even more efficiently by the treatment 
with IL-7/anti-IL-7 complexes [38]. Based on these findings recombinant 
cytokine administration, and in particular BAFF, might well be envisaged as a 
potential therapeutic strategy for patients with immunodeficiencies caused by 
deficient production of a certain cytokine.    
 
Acknowlegments 
BAFF-deficient mice were kindly provided by Susan Kalled (BiogenIdec, 
Cambridge). 
 
 
 
 
 
 
 
Figures legends 
Swee et al                                                                                         Page 12 
 
Figure 1. Production of recombinant Fc-BAFF protein. 
A, Schematic representation of the fusion protein consisting of the human 
Fcγ1 moiety and the receptor binding part of human BAFF (amino acids 136 
to 285). B, SDS-PAGE and Coomassie Blue staining analysis of Fc-BAFF 
under reducing (lane 1) and non-reducing conditions (lane 2). XXX µg of Fc-
BAFF was loaded per lane. C, Gel permeation chromatography of Fc-BAFF 
on a Superdex-200 column. 1 ml fractions were collected, in which Fc-BAFF 
content was determined by an anti-human Fcγ1 ELISA. Broken lines 
represent the elution position of the standard proteins tyroglubuline (440 kDa) 
and catalase (232kDa). D, Hypothetic schematic structure of native Fc-BAFF. 
E, Binding of Fc-BAFF to mouse BAFF-R, mouse TACI and mouse BCMA 
transfected in SP2/0 cells. Grey filled histograms represent the negative 
controls. 
 
Figure 2. Recombinant Fc-BAFF induces B cells survival in vitro. 
CD19+ splenic WT B cells were sorted and incubated in medium alone or in 
the presence of the indicated concentrations of Fc-BAFF. At day 0 (“input”) or 
after 5 days, cells were harvested and stained for CD19 together with 
propidium iodide. Numbers in the dot plots represent the percentages of live 
cells recovered under the various culture conditions. 
 
Figure 3. Recombinant Fc-BAFF treatment rescues mature B cell 
development in BAFF-deficient mice. 
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BAFF-deficient mice were injected at day 0 with 100 µg Fc-BAFF i.v. and at 
day 14 with 50 µg Fc-BAFF i.p.. At day 21, splenic B cell compartments of 
WT, control BAFF-deficient and Fc-BAFF-treated BAFF-deficient mice were 
analysed by flow cytometry. A, CD19 and CD93 expression by splenic cells 
from WT (left dot plot), control (middle dot plot) or injected BAFF-deficient 
mice (right dot plot). B, CD21 and CD23 expression of CD19+CD93- mature 
splenic B cells from WT (left dot plot), control (middle dot plot) or injected 
BAFF deficient mice (right dot plot). C, Absolute numbers (+/- SD) of 
immature and mature splenic B cell subpopulations from WT (black bars), 
control BAFF-deficient (light grey bars) and injected BAFF-deficient mice 
(dark grey bars). 
 
Figure 4. Restoration of the splenic T and B cell architecture in Fc-BAFF-
injected BAFF-deficient mice. 
BAFF-deficient mice were injected at day 0 with 100 µg Fc-BAFF i.v. and at 
day 14 with 50 µg Fc-BAFF i.p.. At day 21, injected BAFF-deficient mice were 
sacrificed together with WT and control BAFF-deficient mice and splenic T 
and B cell architecture was analysed by fluorescence microscopy on 
cryosections. A, Spleen sections of WT (left picture), BAFF-deficient (middle 
picture) or injected BAFF-deficient mice (right picture) were stained for IgM 
(red) and CD90 (green). B, Spleen sections of the same mice were stained for 
IgM (green) and MOMA (red). 
 
Figure 5. BAFF-deficient mice injected with Fc-BAFF mount normal T cell-
dependent humoral immune responses. 
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BAFF-deficient mice were injected at day 0 with 100 µg of Fc-BAFF i.v., and 
at days 14 and 21 with 50 µg Fc-BAFF i.p.. At day 15, WT, BAFF-deficient or 
injected BAFF-deficient mice were immunized i.p. with NIP-CGG in alum. 
Anti-NIP IgG titers were measured by ELISA in the serum of WT, BAFF-
deficient or injected BAFF-deficient mice at day 29 and compared to pre-bleed 
titers (day 14). *: p value ≤ 0.05 **: p value ≤ 0.01 on student T test. 
 
Figure 6. Kinetics of mature B cell disappearance in the absence of a Fc-
BAFF-mediated survival signal.  
A, BAFF-deficient mice were injected at day 0 with 100 µg of Fc-BAFF i.v. and 
at day 14 with 50 µg of Fc-BAFF i.p.. Percentages of mature CD19+CD93- B 
cells were analysed in peripheral blood 1, 3 or 5 weeks after the last Fc-BAFF 
injection. B and C, WT mice were injected i.v. with 50 µg of Fc-BAFF. B, Fc-
BAFF concentrations were measured in the serum at different time points by 
an anti-hBAFF ELISA. C, Mice were sacrificed after 96 hrs. The presence of 
Fc-BAFF at the surface of spleen cell of WT control or Fc-BAFF injected mice 
was analysed using a monoclonal antibody directed against human Fcγ1 
together with CD19 staining. 
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Materials and Methods 
 
Experiment animals 
C56BL/6 mice were obtained from RCC (Füllinsdorf, Switzerland) or Harlan 
Netherlands (Horst, The Netherlands) or bred in an animal facility under 
pathogen-free conditions at the Center of Biomedicine of Basel or at the 
Biochemistry Department of the University of Lausanne. BAFF-deficient mice 
(Schiemann 2001) were bred at the Biochemistry Department of the 
University of Lausanne. All animal experiments were carried out within 
institutional guidelines with the permission of national or local authorities 
(authorization numbers 1370, 1886, 1887 and 1888). 
 
Recombinant Fc-BAFF 
The Fc-BAFF expression plasmid encodes the hemagglutinin signal peptide, 
the Fc portion of human IgG1 (amino acids 108-338 of GenBank accession 
number AAC82527, excluding the stop codon), a linker sequence 
(RSPQPQPKPQPKPEPEGSLQVD) and the receptor-binding domain of 
human BAFF (amino acids 136-285) (Bossen 2007 JBC). An IRES-GFP 
EcoRI/SalI fragment of pMIG-IRES-GFP was cloned in the EcoRI/XbaI sites 3’ 
of the Fc-BAFF construct. Chinese hamster ovary cells were transfected using 
Lipofectamine (Invitrogen) according to the manufacturer's protocol and 
selected 24 h later with 0.5 mg/ml of G418 (Invitrogen). After 14 days of 
selection, GFP-bright cells were sorted using a FACS aria (BD Biosciences), 
amplified and grown in 2-liter roller bottles for 14 d at 37°C. Fc-BAFF was 
Swee et al                                                                                         Page 16 
purified on protein A-Sepharose, eluted with 100 mM citrate-NaOH (pH 2.8) 
and dialysed against PBS. 
SDS-PAGE 
Fc-BAFF was resolved by 12% SDS-PAGE in presence or absence of 50 mM 
DTT. Proteins were stained with Coomassie Blue. 
Gel permeation chromatography 
180 µg of Fc-BAFF was applied onto a Superdex 200 column (GE Healthcare) 
eluted in PBS at 0.5 ml/min. Fractions of 1 ml were collected of which 5 µl 
were analyzed by ELISA against human IgG1. 
  
ELISA 
Unlabeled goat anti-human IgG1 and alkaline phosphatase-coupled goat anti-
human IgG1 were purchased form SouthernBiotech. An anti-human BAFF 
sandwich ELISA was developed in our laboratory. Unlabelled anti-human 
BAFF mAb 2.81.5 was used for capture. Human BAFF was subsequently 
revealed with biotinylated-anti-human BAFF mAb 4.62, followed by alkaline 
phosphatase-coupled streptavidin (Amersham Biosciences, Little Chalfont, 
UK).   
 
Fc-BAFF treatment and immunization of mice 
Unless specified otherwise in the figure legend, mice were injected i.v. at day 
0 with 100 µg of Fc-BAFF in PBS, and then injected i.p. at day 14 with 50 µg 
of Fc-BAFF in PBS. In the immunization experiment, treated mice were 
immunized i.p. with 100 µg of NIP-CGG in alum at day 15, and administered 
with an additional 50 µg of Fc-BAFF i.p at day 21. Anti-NIP IgG titers were 
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measured by ELISA with coated NIP-BSA two weeks post-immunization (day 
29). 
 
Antibody and flow cytometry 
Anti-CD19-PE-Cy7 (1D3) and anti-CD19-PECy5 (1D3) were purchased from 
BD Bioscience (BD Pharmingen). Anti-CD93 (PB493), anti-CD19 (1D3), anti-
CD21 (7G6), anti-CD23 (B3B4), anti-CD90 (T24), and anti-IgM (M41) purified 
and labelled with biotin, Alexa (488) or Alexa (647) using standards 
procedures. Biotin-labelled antibodies were revealed by steptavidin-PE 
(SouthernBiotech), -PECy or -APC (BD Pharmingen).  Staining of cells was 
performed as described previously. Propidium iodide was used at 0.5 µg/ml. 
Flow cytometry was performed using a FACS Calibur (BD Biosciences) and 
data were analyzed using the FlowJo software. 
 
Immunohistochemistry 
Spleens were snap frozen and embedded into OCT (Sakura, Zoetermeer, 
NL). Cryostat sections of 5 µm were prepared and fixed for 10 minutes. 
Sections were stained with anti-IgMbiot (M41) and anti-CD90fitc (T24) or anti-
IgMfitc (M41) and MOMAbiot. Biotin-labelled antibodies were revealed with 
Fluorochrome-coupled streptavidin. Fluoresence was visualized using an 
Axioskop Immunofluorescence (Zeis, Feldbach, Switzerland) equipped with a 
Nikon digital camera. 
 
In vitro B cell survival assay 
Swee et al                                                                                         Page 18 
CD19+ cells were sorted form the spleen of C57BL/6 WT mice using a FACS 
aria (BD Biosciences) and seeded at 2x105 cells/wells in 96 wells plates in 
100 µl medium, in the presence or absence of the indicated concentrations of 
Fc-BAFF. After 5 days of culture, percentages of living cells were estimated 
by flow cytometry using propidium iodide and anti-CD19 stainings. 
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